TRANSCRIPT

Q3 2026 — Prepared remarks

Q3 2026PDF · 12 pages189 KB
Third Quarter 2026 Results
Teleconference Prepared Remarks
October 13, 2026
Moderator:
Good morning, and welcome to the UnitedHealth Group Third Quarter 2026
Earnings Conference Call. A question and answer session will follow
UnitedHealth Group’s prepared remarks. As a reminder, this call is being
recorded.
Here is some important introductory information. This call contains “forward-
looking” statements under U.S. federal securities laws. These statements are
subject to risks and uncertainties that could cause actual results to differ
materially from historical experience or present expectations. A description of
some of the risks and uncertainties can be found in the reports that we file with
the Securities and Exchange Commission, including the cautionary statements
included in our current and periodic filings.
This call will also reference non-GAAP amounts. A reconciliation of the non-
GAAP to GAAP amounts is available on the “Financial & Earnings Reports”
section of the Company’s Investor Relations page at
www.unitedhealthgroup.com.
Information presented on this call is contained in the Earnings Release we issued
this morning and in our Form 8-K dated October 13, 2026, which may be
accessed from the Investor Relations page of the Company’s website. I will now
turn the conference over to the chairman and chief executive officer of
UnitedHealth Group, Steve Hemsley.
Steve Hemsley
Good morning and thank you for joining us today.
Our third quarter performance reflects actions taken throughout 2026, driving
meaningful progress and reinforcing our confidence to sustainably grow in 2027
and beyond within our 13 to 16% long-term target growth range.
Our revised full-year 2026 guidance reflects continuing improvements in
leadership and execution across Optum and UnitedHealthcare as we better align

-- 1 of 12 --

our businesses to serve the demands of the ever-changing U.S. healthcare
environment.
We are accelerating the modernization of our enterprise by advancing simplified
and more responsive policies, processes and tools; focusing on more effective
integrated value-based care offerings; and responsibly building modern agentic
infrastructure as we seek to ensure people have access to higher-quality care at
lower costs, and at the same time clinicians experience a simpler, faster and
more supportive system.
Across the businesses, AI-enabled capabilities are beginning to help clinicians
spend more time with patients, improve service speed and experience,
streamline administration and reduce friction for both consumers and clinicians. A
few examples:
• 	We have expanded AI-enabled chart summarization to more than 40% of
our employed clinicians, reducing chart review time by 33%;
• 	AI-enabled information gathering and research have shortened appeal
cycle times by 26%, improving both member and clinician experience, and
we expect this to accelerate in 2027;
• 	And for this year’s Medicare Advantage Annual Enrollment Period, we are
introducing AI-powered plan recommendations that use a member’s care
history and local plan options to help simplify their selection.
By the end of this year, we are on track to implement all previously announced
prior authorization reforms, reducing decision timelines for patients, relieving
administrative burden for clinicians and delivering better experiences for people.
Collectively, these initiatives will reduce total prior authorizations by 30%,
including a reduction of two-thirds in prior authorizations for people under the age
18.
These efforts are only the beginning – more will follow. They are central to how
we are changing our enterprise to be more in line with our mission, creating
greater value and positive social impact.
In that vein, an important effort is the reimagined United Health Foundation. With
$1 billion committed to date, the foundation’s investments, along with the

-- 2 of 12 --

dedicated operational expertise of UnitedHealthcare and Optum, can help
facilitate scaled solutions to some of the U.S. health system’s greatest
challenges, including rural health, maternal and infant health, behavioral health
and workforce education. As just one example, in Tennessee, the Foundation is
helping expand and operate health hubs across the state, providing access to
underserved communities in preventive care and chronic condition support. We
will continue to highlight the foundation as part of our commentary on our
earnings calls going forward.
The broader health care environment remains dynamic. Policy-driven regulatory
developments, changing consumer expectations and the rapid evolution of
clinical care, and advances in technology continue to reshape the industry.
These factors are pressuring basic affordability and access as never before.
Success requires continuous adaptation – and the pace is accelerating.
We recognize this and remain restless in our pursuit of change and improvement.
We are challenging our assumptions, revising policies and practices and
repositioning leadership and capabilities to better meet the needs of those we
serve and to move faster as an enterprise to adapt to the changing healthcare
landscape. That includes opportunities to better align with clinical partners,
employers and government benefits sponsors, to help improve the experience of
all stakeholders in healthcare.
We have made progress in our 2026 performance. We have much to do to
approach the full potential of our mission and the positive impact we can make as
an enterprise. UnitedHealth Group has a long history of evolution to meet the
needs of a changing U.S. health system. We are committed to accelerating these
efforts as a stronger, more capable, more mission-centered enterprise.
With that, let me turn the call over to Tim Noel.
Tim Noel
Thanks, Steve.
UnitedHealthcare is seeing positive momentum across our Medicare and
Medicaid businesses, while our commercial business continues to adjust to a

-- 3 of 12 --

challenging but steadily stabilizing environment. Costs remain stubbornly high
across the entire healthcare landscape, and particularly in areas such as
specialty pharmacy and acute healthcare service intensity.
We continue to address the challenge of increasingly expensive care with
appropriate medical management, operational discipline and a commitment to
identify and remove excess and unnecessary costs from our own enterprise as
we advance simpler and more modern services. We are working to deliver stable
benefits and value for our members and customers. We believe this positions us
for continued organic growth and long-term value creation entering 2027.
Let me start with our Medicare business, where the Annual Enrollment Period
begins later this week.
Medicare Advantage remains the choice of well more than half of eligible
American seniors as it offers better and more modern benefits and, importantly,
better outcomes than fee-for-service Medicare. Beneficiaries choosing Medicare
Advantage save on average more than $4,000 annually through lower premiums
and cost sharing, than those on original Medicare.
With adequate funding, we believe Medicare Advantage will continue to be the
choice of American seniors, particularly those who are disadvantaged and have
chronic care challenges as they seek better value and modern care.
Heading into 2026, we made deliberate decisions regarding Medicare Advantage
benefit design and market positioning to preserve the long-term sustainability and
performance of our Medicare Advantage offerings. We continued this disciplined
approach for 2027.
We believe we are competitively positioned, focused on providing value for
seniors in the markets we serve while being mindful of trend dynamics. In 2027,
UnitedHealthcare will continue to prioritize high-value HMO, chronic special
needs and dual special needs offerings.
Our commitment to serving America’s seniors is clear: More than 94% of
Medicare eligible individuals nationwide will have access to a UnitedHealthcare
Medicare plan, and approximately 90% of Medicare-eligible consumers will have
access to one of our Medicare Advantage plans with a $0 premium option. We

-- 4 of 12 --

are maintaining important benefits such as dental, vision, hearing and additional
health and wellness offerings that make a real difference in the lives of seniors.
UnitedHealthcare chronic special needs plans will be available to nearly 50
million Medicare-eligible individuals in 2027, providing specialized support for
people living with conditions such as diabetes, cardiovascular disease and
chronic heart failure.
These plans offer benefits and access to care tailored to the unique needs of
individuals managing chronic conditions, helping them connect with the care,
medications and support they need.
Much of this work is in coordination with our partners at Optum Health, where
evidence shows chronically complex seniors served by integrated value-based
care experience better preventive care while improving health outcomes at lower
costs. Medicare Advantage patients in value-based care arrangements are 40%
less likely than traditional Medicare patients to be hospitalized for acute and
chronic conditions, and 40% less likely to be readmitted to a hospital within 30
days of discharge.
Moving to Stars…our initial Star ratings for payment year 2028 reflect our
investments in quality, member experience and operating execution. As we move
through 2027 and into 2028, we expect to approach 75% of total members in 4-
plus Star plans, compared to the industry average of 70%. Our team remains
intensely focused on building a best-in-class consumer and clinical experience,
and along with better benefit design and stability going forward, we believe those
efforts will continue translating into stronger quality performance over time. We
will continue to work in support of CMS quality program efforts to ensure the
Medicare Advantage program continues to provide quality experience and
stability to the 36 million seniors who depend on it.
Turning to medical costs, the actions we've taken to improve and modernize care
management, strengthen clinical engagement and enhance operating discipline
are having a meaningful effect. Care intensity remains elevated relative to
historical norms, even as we continue to see signs that trends are bending in a
more stable direction than what we have recently experienced. We remain

-- 5 of 12 --

respectful of trend and are not assuming any deceleration to historical patterns or
to ongoing clinician pricing pressure.
Demand for care remains strong, particularly among senior and complex
populations, and we fully support appropriate access to care for our members.
Turning to the commercial business, performance continues to stabilize as we
navigate a challenging market. As we previously noted, trends for commercial
benefits are exceeding our initial expectations of 11%, driven by an acceleration
of costs related to the No Surprises Act, greater cost intensity from clinicians and
high-cost specialty drugs.
Of particular concern is the ongoing abuse of the No Surprises Act dispute
process by a relatively small number of clinician groups and third-party
organizations. Arbitration awards can approach nearly 6% of total medical spend
in some regions, translating to billions of dollars in excess costs for consumers,
employers and the health system.
The law was intended to protect patients from unexpected bills, and we strongly
support that objective. We will continue working with policymakers and regulators
to ensure the law functions as intended and that healthcare dollars are directed
toward appropriate patient care rather than significantly inflated market arbitration
awards and volumes along with unnecessary administrative expense.
Medicaid remains stable through the back half of the year while our team
continues to drive greater operational improvements through network curation
and more effective behavioral health program initiatives. These actions help to
partially offset the primary variable, which continues to be the timing and
adequacy of state funding across several markets.
As we move through the balance of 2026, we continue to work collaboratively
with our state partners to ensure rates appropriately reflect the acuity and
healthcare needs of the families being served, including the impacts of regulatory
actions. While progress has been made in many states, the timing of updates
remains uneven.

-- 6 of 12 --

Based on our current outlook, we continue to view 2026 as a trough year for core
Medicaid margins, which we now expect to be moderately better than negative
1%.
Finally, we are focusing intently on enhancing our support for and relationships
with clinicians and health systems. In addition to the prior authorization changes
Steve mentioned, which we see as only the beginning, we are meaningfully
speeding up our claims processing and payments and re-energizing our
relationship engagement efforts with more dedicated resources and executive
ownership. Our goal is to provide a more seamless experience for clinicians and
health systems who work with us, and resolve issues more quickly.
As we look toward 2027 and beyond, we are shifting our focus to sustainable
organic growth underpinned by improving Medicare fundamentals, a stronger
commercial outlook, continued opportunities to enhance Medicaid performance,
and an organization that is operating with greater discipline and accountability for
all our stakeholders.
With that, I’ll turn it over to Patrick.
Patrick Conway
Thanks, Tim.
Our results in the third quarter underscore the important work underway across
all of Optum to lay the groundwork for long-term growth.
Starting with Optum Health…
Overall, Optum Health continued to deliver strong performance in the third
quarter, driven by the continued return to value-based care principles combined
with strong execution across our clinical programs and operational improvements
enabling clinicians to focus more on their patients and improve patient
experience. A few of the examples for this morning:
• 	A 27% increase from last year in online self-scheduling, making it easier
for patients to reach clinicians.
• 	An increase in home health visits by 10% over last year.

-- 7 of 12 --

• 	And we are very encouraged by the early success of our program to co-
locate behavioral specialists within our primary care practices. The
number of patients referred has doubled since last year, with an
engagement rate of more than 90%.
As Tim mentioned, it is now more important than ever to provide seamless care
and coverage for our chronic and complex patients through all phases of the care
continuum – from primary care, to specialist, to home, to the pharmacy.
Moving to Optum Rx. Our focus in this business continues to be on two efforts to
ensure value alignment to the customers and patients we serve.
First, we continue to increase transparency on the PBM side of Optum Rx.
Through the 2027 selling season, we have seen our industry-first affordability,
experience and transparency initiatives resonating in the marketplace – and
customers (the employers, governments, unions we serve) continuing to
recognize the vital role of PBMs in controlling prescription drug costs and in
ensuring people have access to the medications they need, particularly as the
prices charged by drug manufacturers continue to increase. For the first time,
over 50% of Optum Rx membership is external, non-UHC membership.
Second, we fundamentally believe that pharmacy services have to be closer to
the patient. Accordingly, you will see continued efforts within our separate
pharmacy services businesses to more closely align pharmacy care with medical
care. Integrated value-based care means just that – integrated. When pharmacy
care and medical care are aligned, outcomes improve for the patients we serve,
access improves, and the total cost of care is lowered. Specifically within the
pharmacy services side of Optum Rx:
• 	Genoa continues to expand its dedicated behavioral health pharmacy
footprint and serve patients with serious mental illness and substance-use
disorders,
• 	Specialty pharmacy continues to grow through both volume and mix, while
improving patient support for increasingly complex therapies, and
• 	Infusion services are becoming more important as we help shift
appropriate care into lower-cost and more convenient settings.

-- 8 of 12 --

We will continue to expand our portfolio of integrated pharmacy services and
align them as close to medical care settings as possible, delivering better care,
convenience and access.
Turning to Optum Insight. 2026 has been both a performance and an investment
year. And 2027 will show meaningful progress setting the foundation for
accelerating growth in '28 and beyond. Our investment focus has been on further
developing and bringing to market healthcare-specific AI solutions that enhance
productivity performance outcomes while improving the patient and clinician
experience.
Overall, we are looking to 2027 with confidence. Our major remediation work is
largely complete and has created a strong foundation for growth across Optum.
With that, I’ll turn it over to Wayne.
Wayne DeVeydt
Thanks, Patrick, and good morning.
Third quarter results reflect continued progress across the enterprise and
improving execution in our businesses where we have been focused on
operating reforms to drive better consumer and clinician experience.
For Q3 2026, we reported revenue of $113 billion, and adjusted earnings per
share of $4.69, up from $2.92 a year ago. Consolidated medical care ratio of
88.4% for the quarter compares to 89.9% last year. The quality of our earnings is
strong and durable as we head into 2027.
At UnitedHealthcare, performance continued to reflect pricing discipline,
fundamental medical cost management, and care delivery enhancements. We
continue to be respectful of continued elevated utilization trends, which typically
step up in the back half of the year, particularly in our risk-based businesses.
Within Optum Health, we are seeing steady progress from modernization, a
return to a disciplined value-based care approach and operating improvements
as the actions taken through 2026 begin to yield results.
In Optum Insight, performance is benefiting from technology and AI-enabled
improvements, including payment integrity and broader operating efficiency,

-- 9 of 12 --

while we invest into new areas to expand and modernize our offerings to drive
growth.
And in Optum Rx, we continue to see the benefits of disciplined execution and
the breadth of our pharmacy services model, now based on a simpler, more
transparent approach to serving these evolving market needs.
Turning to the full year, our updated 2026 adjusted EPS guidance of at least
$20.50 reflects performance through the third quarter, balanced by expected
investments in the final months of the year.
From a capital deployment perspective, our priorities remain consistent: first,
reinvest in the business through targeted organic growth and steady expansion in
care delivery, technology modernization and broad-based AI adoption; second,
maintain balance sheet strength; and third, return value to shareholders.
Our balance sheet remains strong. Our debt-to-capital ratio was 41.7% at the
close of the quarter, and we remain on track to approach 40% by year end.
We repurchased $5 billion of UNH stock through the third quarter. We have paid
$6.2 billion in dividends year to date and expect to exceed $8 billion by year-end.
Our strategic priorities remain focused on capabilities that align with and
strengthen our ability to deliver value to consumers, benefit sponsors and
customers, and support long-term growth for shareholders.
We view our 2026 adjusted EPS guidance of at least $20.50 as a solid run rate
on which to grow. We would offer that current analyst consensus for 2027 may
understate the opportunity ahead, and we see the lower end of our long-term 13-
to-16% growth rate as a more reasonable starting point.
As we think about 2027 more broadly, we continue to see a balanced set of
tailwinds and headwinds. Tailwinds include continued enterprise-level
performance progress, share repurchases, value-based care performance
improvements, and further gains from AI and modernization that improve both
consumer and clinician experiences, drive productivity benefits, reduce costs and
create sustainable performance improvement opportunities for our business and
those we serve, as well as product opportunities for Optum Insight. On the
headwinds side, we will accelerate our investments in the policy reforms and

-- 10 of 12 --

modernization of the businesses, particularly in UnitedHealthcare and Optum
Insight, and remain respectful of medical trend and the broader external
environment, where health benefits funding remains pressured.
Overall, we are steadily and methodically improving performance broadly across
the portfolio. We are positioned to finish 2026 strongly, and we remain focused
on consistently delivering our 13 to 16% long-term growth target.
With that, I’ll turn it back over to Steve.
Steve Hemsley
Thanks, Wayne.
Let me close with a few thoughts before we move to questions.
For a little more than a year, our priorities have been clear:
• 	Return to our core mission and culture;
• 	Better serve the needs of healthcare as one enterprise and one leadership
team;
• 	Restore financial and operating discipline;
• 	Turnaround and strengthen our performance – business by business,
across all performance measures;
• 	Begin the process of reimagining and modernizing all we do to harness
the compelling potential of modern intelligent technologies;
• 	Simplify our processes, elevate our service levels and advance our
response and service speed to consumers and clinicians;
• 	And finally, reposition all our businesses to return to responsible levels of
profitable organic growth.
As you have heard today, we are well underway in all those areas. But fully
achieving those priorities requires us to get outside our four walls.
Throughout our company, we are spending time listening carefully to customers,
consumers, clinicians, policymakers and other stakeholders. We are doing so

-- 11 of 12 --

with humility and with a service mindset, conscious of the positive role we can
play and the responsibility we have to improve the health system experience
when we operate at our best.
Those conversations are helping renew and reinforce the fundamental
understanding that success in health care depends on relationships and trust.
And we need to continue to build both with all our stakeholders.
We will continue listening. We will continue learning. And we will continue
advancing our business in ways that improve experiences, provide easier access
and lower costs while delivering better outcomes – and for you, our shareholders,
all these accountabilities align and create value.
The progress we have made in 2026 gives us confidence. Our businesses are
improving. Our modernization efforts are gaining traction. Our investments in AI
and in integrated value-based care are creating tangible benefits today while
positioning us for the future.
We remain focused on better managing our businesses, finishing ‘26 strong, and
building that foundation for growth in ’27 and ‘28 and beyond.
We look forward to providing a more comprehensive update on our outlook for
next year before year-end.
Thank you. Now, operator, let's open the line for questions.
Post Q&A Steve Close
Thank you again for your time today. I hope you got a sense of the momentum
we are bringing into 2027 as our emphasis on discipline, execution and improved
patient and care provider experiences take hold. We look forward to providing
you with a more complete look at 2027 in December.

-- 12 of 12 --